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Abstract
Background and Purpose: Little attention has been paid to the pathogenesis of in-hospital 
stroke, despite poor outcomes and a longer time from stroke onset to treatment. We studied 
the pathophysiology and biomarkers for detecting patients who progress to in-hospital isch-
emic stroke (IHS). Methods: Seventy-nine patients with IHS were sequentially recruited in the 
period 2011–2017. Their characteristics, care, and outcomes were compared with 933 patients 
who had an out-of-hospital ischemic stroke (OHS) using a prospectively collected database 
of the Tokushima University Stroke Registry. Results: Active cancer and coronary artery dis-
ease were more prevalent in patients with IHS than in those with OHS (53.2 and 27.8% vs. 2.0 
and 10.9%, respectively; p < 0.001), the median onset-to-evaluation time was longer (300 vs. 
240 min; p = 0.015), and the undetermined etiology was significantly higher (36.7 vs. 2.4%; 
p < 0.001). Although there was no significant difference in stroke severity at onset between 
the groups, patients with IHS had higher modified Rankin Scale (mRS) scores (3–6) at dis-
charge (67.1 vs. 50.3%; p = 0.004) and rates of death during hospitalization (16.5 vs. 2.9%; p < 
0.001). D-dimer (5.8 vs. 0.8 µg/mL; p < 0.001) and fibrinogen (532 vs. 430 mg/dL; p = 0.014) 
plasma levels at the time of onset were significantly higher in patients with IHS after propen-
sity score matching. Multivariate logistic regression analysis revealed that active cancer (odds 
ratio [OR] 2.30; 95% confidence interval [CI] 1.26–4.20), prestroke mRS scores 3–5 (OR 6.78; 
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95% CI 3.96–11.61), female sex (OR 1.57; 95% CI 1.19–2.08), and age ≥75 years (OR 2.36; 95% 
CI 1.80–3.08) were associated with poor outcomes. Conclusions: Patients with IHS had poor-
er outcomes than those with OHS because of a higher prevalence of active cancer and func-
tional dependence before stroke onset. Elevated plasma levels of D-dimer and fibrinogen, 
especially with active cancer, can help identify patients who are at a higher risk of progression 
to IHS. © 2019 The Author(s)
Published by S. Karger AG, Basel
Introduction
In-hospital ischemic stroke (IHS) is an acute stroke in patients admitted to hospital with 
another diagnosis or for a different procedure. These patients present with distinct risk 
factors and worse outcomes than out-of-hospital ischemic stroke (OHS) patients [1]. An esti-
mated 2.2–17% of acute strokes are of in-hospital onset [2]. However, less attention has been 
paid to the pathogenesis of IHS, despite poor outcomes and the longer time from stroke onset 
to treatment. 
Many stroke patients have been treated at our stroke center, established in 2005, with 
various therapeutic options, including patients with IHS and OHS. Their data, including char-
acteristics, care, and outcomes, are compiled by the Tokushima University Stroke Registry. 
We believe that it is crucial to clarify the differences between patients with IHS and OHS, to 
be able to develop strategies to reduce the incidence of IHS. 
Several studies have examined the prognostic and diagnostic implications of elevated 
D-dimer as a risk factor for stroke in patients with cancer and cardiovascular diseases [3–6]. 
Although plasma D-dimer levels reflect fibrin turnover and are a unique thrombosis 
biomarker, levels that predict ischemic stroke are unknown. Stroke is often observed in 
patients with cancer or cardiovascular disease and is a devastating event with high mortality; 
however, predictors of mortality in patients with IHS who have a history of cancer and/or 
cardiovascular disease are poorly elucidated. Furthermore, the timing of IHS onset remains 
unclear. 
We examined characteristics, care, and outcomes in patients with IHS. These data were 
compared to the same parameters measured in patients with OHS. We also investigated the 
pathophysiology of IHS and biomarkers for the early detection of patients at a high risk of 
progression to IHS. 
Materials and Methods
Patient Recruitment and Characteristics
This retrospective analysis used prospectively collected stroke registry data obtained 
from consecutive patients admitted and treated for ischemic stroke in the Stroke Center at 
Tokushima University Hospital between January 2011 and December 2017. We determined 
stroke subtypes using 12 channel electrocardiograms, 24-h electrocardiogram monitoring, 
echocardiography, carotid ultrasonography, and brain magnetic resonance imaging. Figure 
1a shows the case-selection flowchart of the study. Among 1,178 ischemic stroke patients, 
those with a transient ischemic attack (n = 124), IHS at another hospital and subsequently 
admitted to our hospital (n = 31), IHS at the Department of Neurology/Neurosurgery (n = 7), 
and those with insufficient data to distinguish IHS from OHS (n = 4) were excluded from this 
study. In total, 1,012 ischemic stroke patients were finally included in this study. These 
patients were divided into 2 groups: the IHS group, i.e., when the stroke occurred in hospital, 
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and the OHS, i.e., when the stroke occurred outside the hospital. We conducted between-
group comparisons of demographics, past medical history, medications taken before stroke, 
the prestroke modified Rankin Scale (mRS) score, the National Institutes of Health Stroke 
Scale (NIHSS) score at stroke onset, onset-to-evaluation (OTE) time, the stroke subtype 
using the Trial of ORG 10172 in Acute Stroke Treatment (TOAST) classification [7], mRS 
score at discharge, mortality during hospitalization, and the levels of plasma D-dimer and 
fibrinogen.
The OTE time was defined as the time point of stroke physician evaluation minus the time 
point of stroke onset. Stroke onset times were decided as the time the patient was last known 
to be well or that the onset of symptoms was noticed. A poor outcome was defined as an mRS 
score of 3–6 at discharge, or in-hospital death. Primary diseases for the admission of patients 
with IHS were classified using the International Statistical Classification of Diseases and 
Related Health Problems, Tenth Revision (ICD-10) coding of disease entities [8]. All cancers 
were staged using the tumor-node-metastasis (TNM) classification system from the Union for 
International Cancer Control (UICC) for solid cancers or the Ann Arbor classification for 
malignant lymphoma [9, 10]. Active cancer was defined as cancer diagnosed within 6 months 
before stroke onset, any treatment for cancer within the previous 6 months, or recurrent or 
metastatic cancer [11]. Patients with cancer-related ischemic strokes were those with (a) a 
stroke of undetermined etiology, (b) active cancer, and (c) elevated D-dimer levels (≥1.0 µg/
mL). 
Plasma levels of coagulation markers, including D-dimer, were elevated in patients with 
acute ischemic stroke and cancer or cardiovascular diseases [3, 4, 12, 13]. These findings 
might reflect the hypercoagulable state of stroke patients. The plasma levels of D-dimer and 
fibrinogen within 72 h of stroke onset were compared between patients with IHS and OHS 
after propensity score-matching to adjust for age, sex, hypertension, diabetes mellitus, dyslip-
idemia, and atrial fibrillation (AF). 
Statistical Analysis
Comparisons were performed using the Wilcoxon rank-sum test for continuous variables 
and the χ2 test for categorical variables. Univariate and multivariate logistic regression 
analyses were performed to identify factors associated with poor outcomes (mRS 3–6 at 
discharge). The stepwise forward selection method was used to select the variables for multi-
variate analysis. The p value threshold for entry was set at 0.05. Propensity score-matching 
was conducted to adjust for age, sex, hypertension, diabetes mellitus, dyslipidemia, and AF 
between patients with IHS and OHS. All statistical analyses were performed using JMP®13 
(SAS Institute Inc., Cary, NC, USA) and p < 0.05 was considered statistically significant.
Results
Differences in Baseline Characteristics and Care between Patients with IHS and OHS 
We examined the data on 1,012 patients with ischemic stroke, 79 of whom (7.8%) had 
IHS, and 933 of whom (92.2%) had OHS, similar to a previous report [2]. Patients with IHS 
were younger (mean age 68.5 vs. 72.7 years; p = 0.006), and more likely to have coronary 
artery disease (27.8 vs. 10.9%; p < 0.001) and active cancer (53.2 vs. 2.0%; p < 0.001) than 
patients with OHS (Table 1). In IHS patients, prestroke mRS 3–5 (functional dependence) was 
higher than in OHS patients (30.4 vs. 12.4%; p < 0.001), mostly due to the primary disease 
condition. There were no significant between-group differences regarding the use of anti-
thrombotic agents and statins or stroke severity. Importantly, patients with IHS had a signif-
icantly longer OTE time than OHS patients (median 300 vs. 240 min; p = 0.015). Although 
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there was no significant difference between the 2 groups, patients with IHS tended to receive 
intravenous thrombolytic therapy less often than patients in the OHS group (6.3 vs. 11.7%; 
p = 0.121). The rate of endovascular therapy was not significantly different between the 
groups (13.9 vs. 13.3%; p = 0.874).
Most Patients with IHS Had Neoplasms or a Disease of the Circulatory System at 
Admission 
Neoplasms (53.2%) were the most prevalent primary disease in patients with IHS (online 
suppl. Table 1; for all online suppl. material, see www.karger.com/doi10.1159/000504163). 
Approximately 80% of patients with IHS had neoplasms (Chapter II, C00–D48) or diseases of 
the circulatory system (Chapter IX, I00–I99). The most frequent cancer type was lung cancer 
(35.7%) (online suppl. Table 2). Histologically, the frequency of adenocarcinoma was high 
(59.5%). Patients with active cancers were primarily diagnosed with advanced-stage disease 
and 81.0% of them were stage III or IV disease. 
Table 1. Baseline characteristics and care between patients with IHS and OHS
IHS OHS p value
(n = 79) (n = 933)
Demographics
Male sex 51 (64.6) 577 (61.8) 0.632
Age, years (mean ± SD) 68.5±13.0 72.7±12.8 0.006*
Medical history
Hypertension 46 (58.2) 630 (67.5) 0.098
Diabetes mellitus 26 (32.9) 257 (27.5) 0.315
Dyslipidemia 14 (17.7) 157 (16.8) 0.840
Atrial fibrillation 15 (19.0) 155 (16.6) 0.593
Stroke/TIA 13 (16.5) 155 (16.6) 0.971
Smoking 31 (39.2) 373 (40.0) 0.898
Hemodialysis 1 (1.3) 6 (0.6) 0.562
Coronary artery disease 22 (27.8) 102 (10.9) <0.001*
Active cancer 42 (53.2) 19 (2.0) <0.001*
Medications before stroke
Antiplatelet agent 19 (24.1) 212 (22.7) 0.788
Anticoagulant agent 13 (16.5) 111 (11.9) 0.254
Statin pretreatment 10 (12.7) 128 (13.7) 0.790
Prestroke mRS score
0–2 55 (69.6) 817 (87.6) <0.001*
3–5 24 (30.4) 116 (12.4) <0.001*
NIHSS score at stroke onset 6 (2–16) 4 (2–12) 0.127
(n = 67) (n = 923)
Onset-to-evaluation time 300 (113–1,440) 240 (90–540) 0.015*
(n = 74) (n = 775)
Type of treatment
Intravenous thrombolysis 5 (6.3) 109 (11.7) 0.121
Endovascular therapy 11 (13.9) 124 (13.3) 0.874
Values are expressed as n (%) or median (interquartile range), unless otherwise specified. IHS, in-hospital 
ischemic stroke; OHS, out-of-hospital ischemic stroke; TIA, transient ischemic attack; mRS, modified Rankin 
Scale; NIHSS, National Institutes of Health Stroke Scale. * p < 0.05, statistically significant.
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Patients with IHS and Active Cancers Had Poorer Outcomes
Rates of large-artery atherosclerosis and small-vessel occlusion were lower in IHS 
patients than in OHS patients (20.3 vs. 34.3% [p = 0.008] and 2.5 vs. 25.7% [p < 0.001], respec-
tively) (Fig. 1b). There were no significant between-group differences for cardioembolism or 
stroke of determined etiology. Interestingly, there was a markedly higher prevalence of 
stroke of undetermined etiology in IHS patients than in OHS patients (36.7 and 2.4%, respec-
tively; p < 0.001). Twenty-two of the 42 patients with IHS (52.4%) with active cancer were 
registered as having cancer-related ischemic stroke, indicating the importance of cancer in 
the pathology of IHS. Functional impairment at discharge, as assessed by the mRS, trended 
toward poorer outcomes in patients with IHS (Fig. 1c). mRS scores of 3–6 at discharge (67.1 
IHS vs. 50.3% OHS; p = 0.004) and mortality during hospitalization (16.5 IHS vs. 2.9% OHS, 
p < 0.001) were significantly higher in patients with IHS, suggestive of poorer outcomes. 
Multivariate logistic regression analysis revealed that female sex (odds ratio [OR] 1.57; 95% 
confidence interval [CI] 1.19–2.08), age ≥75 years (OR 2.36; 95% CI 1.80–3.08), active cancer 
(OR 2.30; 95% CI 1.26–4.20), and prestroke mRS 3–5 (OR 6.78; 95% CI 3.96–11.61) were 
independent factors associated with poorer outcomes (Table 2). Statin pretreatment (OR 
0.61; 95% CI 0.41–0.91) was a protective factor for favorable outcomes. Importantly, outcomes 
were not related to in-hospital onset per se, but to a patient’s background.
Tokushima University Stroke Registry 2011–2017
(n = 2,284)
• Hemorrhagic stroke (n = 783)
• Stroke mimics (n = 323)
• TIA (n = 124)
• IHS at another hospital and 
 admitted to our hospital (n = 31)
• IHS at the Department of
 Neurology/Neurosurgery (n = 7)
• Insufficient data to distinguish
 IHS from OHS (n = 4)
Ischemic stroke (n = 1,178)





Excluded (n = 1,106)






OHS 49.7 47.4 2.9






























































Fig. 1. a Case-selection flowchart. b Stroke subtypes in patients with IHS and OHS. c mRS at discharge in pa-
tients with IHS and OHS. d Left: D-dimer levels in patients with IHS (n = 56; median 5.8; IQR 2.3–15.1) and 
OHS (n = 56; median 0.8; IQR 0.5–1.2). Right: fibrinogen levels in patients with IHS (n = 56; median 532; IQR 
395–698) and OHS (n = 56; median 430; IQR 381–528). IHS, in-hospital ischemic stroke; OHS, out-of-hospital 
ischemic stroke; TIA, transient ischemic attack; LAA, large-artery atherosclerosis; CE, cardioembolism; SVO, 
small-vessel occlusion; D, stroke of determined etiology; U, stroke of undetermined etiology; mRS, modified 
Rankin Scale. ** p < 0.01; # p < 0.001.
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Table 2. Multivariate logistic regression analysis model of the probability of a poor outcome, i.e. an mRS score of 3–6 at discharge
Factors Patients with an
mRS score 3–6
Univariate analysis Multivariate analysis
n % OR (95% CI) p value OR (95% CI) p value
In-hospital onset
No 933 50.3 1 (ref.) –
Yes 79 67.1 2.02 (1.24–3.28) 0.004*
Gender
Male 628 45.9 1 (ref.) – 1 (ref.) –
Female 384 60.9 1.84 (1.42–2.38) <0.001* 1.57 (1.19–2.08) 0.002*
Age
<75 years 513 39.4 1 (ref.) – 1 (ref.) –
≥75 years 499 64.1 2.75 (2.13–3.55) <0.001* 2.36 (1.80–3.08) <0.001*
Hypertension
No 336 50.6 1 (ref.) –
Yes 676 52.1 1.06 (0.82–1.38) 0.658
Diabetes mellitus
No 729 52.3 1 (ref.) –
Yes 283 49.8 0.91 (0.69–1.19) 0.486
Dyslipidemia
No 841 53.2 1 (ref.)
Yes 171 43.9 0.69 (0.49–0.96) 0.027*
Atrial fibrillation
No 842 49.4 1 (ref.) –
Yes 170 62.4 1.7 (1.21–2.38) 0.002*
A history of stroke/TIA
No 844 52.7 1 (ref.) –
Yes 168 45.8 0.76 (0.54–1.06) 0.103
A smoking history
No 608 56.4 1 (ref.) –
Yes 404 44.3 0.61 (0.48–0.79) <0.001*
Coronary artery disease
No 888 50.6 1 (ref.) –
Yes 124 58.9 1.4 (0.96–2.05) 0.002*
Active cancer
No 951 50.4 1 (ref.) – 1 (ref.) –
Yes 61 70.5 2.35 (1.34–4.14) 0.002* 2.30 (1.26–4.20) 0.007*
Antiplatelet agent
No 781 52.1 1 (ref.) –
Yes 231 49.8 0.91 (0.68–1.22) 0.534
Anticoagulant agent
No 888 50.3 1 (ref.) –
Yes 124 60.5 1.51 (1.03–2.22) 0.034*
Statin pretreatment
No 874 52.9 1 (ref.) – 1 (ref.) –
Yes 138 43.5 0.69 (0.48–0.99) 0.040* 0.61 (0.41–0.91) 0.017*
Prestroke mRS score
0–2 872 45.8 1 (ref.) – 1 (ref.) –
3–5 140 87.9 8.58 (5.08–14.50) <0.001* 6.78 (3.96–11.61) <0.001*
The test and 95% CI for the OR were based on the likelihood ratio; a stepwise forward selection method was used to select the 
variables for multivariate analysis. The threshold for entry was set at p = 0.05. OR, odds ratio; CI, confidence interval; ref., reference; 
TIA, transient ischemic attack; mRS, modified Rankin Scale. * p < 0.05, statistically significant.
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Abnormal Coagulation Was Associated with a Higher Incidence of IHS
Patients with IHS had significantly higher D-dimer (median 5.8 vs. 0.8 µg/mL; p < 0.001) 
and fibrinogen (median 532 vs. 430 mg/dL; p = 0.014) levels than patients with OHS (Fig. 1d). 
There was a high variability in the D-dimer and fibrinogen levels of patients with IHS. This 
relationship remained significant even when we excluded surgery patients (data not shown). 
Thus, patients with IHS were more likely to demonstrate hypercoagulable conditions.
Postoperative Ischemic Stroke
Among 79 patients with IHS, 17 patients (21.5%) had undergone surgery before stroke 
onset. The median interval from the surgical procedure to stroke onset was 2 (IQR 1–5) 
days. The administration of the antithrombotic agent was stopped before surgery in 5 
patients (29.4%). In 1 patient with AF, warfarin administration was stopped for more than 
1 month due to hemorrhagic complications before surgery. In the other patients, the anti-
thrombotic agent was appropriately stopped before surgery and restarted on postoper-
ative day 1 or 2.
Discussion
In this study, we document that neoplasms were the most common primary disease in 
patients with IHS. We found that active cancer and coronary artery disease had a significantly 
higher prevalence in patients with IHS; however, the most classical stroke risk factors did not 
differ from those in the OHS patients. The prevalence of stroke of undetermined etiology was 
higher in patients with IHS, for whom cancer-related ischemic strokes were most common. 
Furthermore, there was a strong relationship between poorer outcomes and active cancer 
rather than with the in-hospital onset per se. Taken together, efforts to improve outcomes in 
patients with IHS should consider the active cancer status.
Cerebrovascular disease is not uncommon in patients with cancer; an autopsy study of 
3,426 patients with systemic cancer revealed the presence of cerebrovascular disease in 500 
(14.6%) patients [14]. In patients with cancer, ischemic stroke is related to poorer outcomes 
and higher recurrence [15]. Adenocarcinoma, particularly, is associated with recurrent 
thromboembolism and these events are occasionally diagnosed during a stay in hospital [15]. 
Importantly, more than half of our patients with IHS had active cancers, with a 59.5% inci-
dence of adenocarcinoma. These factors are thought to contribute to the poor outcomes in 
IHS patients. It was recently reported that embolic stroke of undetermined source (ESUS) was 
not related to long-term outcome [16]. However, a follow-up of ESUS patients, especially 
those with elevated D-dimer and fibrinogen levels, should be performed with occult cancer 
in mind because cancer-related ischemic stroke may be a cause of ESUS.
D-dimer and fibrinogen are indicated as potential biomarkers associated with early 
neurological deterioration following acute stroke in a recent systematic review and meta-
analysis [17]. Levels of D-dimer and fibrinogen are elevated in ischemic stroke patients with 
cancer due to cancer-mediated hypercoagulability [4, 12, 13]; these are also markers of cancer 
progression [18]. Concurrent high D-dimer levels and multiple vascular territory infarctions 
are an independent predictor of early recurrent stroke in patients with active cancers [19]. 
Patients with active cancers who experience arterial ischemic events have a higher rate of 
death than those with venous thromboembolisms [20].
Higher D-dimer levels are associated with a higher risk of stroke [6]. A recent report indi-
cated that higher D-dimer levels on admission were significantly associated with an increased 
incidence of ischemic stroke shortly after admission for acute heart failure [3]. This suggests 
that D-dimer levels may predict short-term ischemic stroke events in patients with acute 
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heart failure. Importantly, our study showed that plasma D-dimer levels were higher in 
patients with IHS. Thus, a high D-dimer level on admission, especially in a patient with active 
cancer, could be an indicator of increased IHS risk. 
Low-molecular-weight heparins and direct oral anticoagulants are recommended for 
the secondary prevention of cancer-related ischemic stroke; however, the available evidence 
has come mainly from venous thromboembolism studies or indirect findings (e.g., decreased 
D-dimer levels or embolic signals) [21]. There is no evidence that prophylactic use of anti-
thrombotic agents for primary prevention of IHS reduces the incidence of cancer-asso-
ciated ischemic strokes; furthermore, patients with cancer have an increased risk of 
bleeding [22].
Brain imaging and the initiation of intravenous thrombolysis or endovascular therapy 
could be delayed after symptoms of ischemic stroke have been recognized in patients with 
IHS, even with no prehospital phase [1, 2]. The IHS group had a longer OTE time, in line with 
other studies. Physicians who initially encounter patients with IHS may be unfamiliar with 
stroke care. The early detection of patients at a high risk of IHS may enable early referral to a 
stroke center.
IHS patients tend to have contraindications, such as intravenous thrombolysis [1], and 
endovascular therapy for major vessel occlusion would improve their outcomes. In recent 
years, endovascular therapy has drastically improved outcomes in patients who sustain 
large-vessel ischemic stroke [23]. Furthermore, early endovascular therapy is associated 
with benefits that may be lost when treatment is delayed [24]. Jung et al. [25] reported that 
ischemic stroke patients with active cancers who underwent endovascular therapy had good 
outcomes, similar to those in patients with cardioembolic and large-artery atherosclerosis. If 
patients at a high risk of IHS are identified at admission, the time from stroke onset to endo-
vascular therapy puncture may shorten. A cancer diagnosis and elevated levels of plasma 
D-dimer and fibrinogen may help to identify patients at a high risk of IHS.
Interestingly, the multivariate logistic regression analysis revealed that the character-
istics common to the IHS patients such as active cancer and prestroke mRS 3–5 (functional 
dependence) were strongly related to poor outcomes rather than the in-hospital onset per 
se. The association of older age and female sex with poor outcomes is consistent with 
recent reports [26]. Statins display neuroprotective effects beyond lipid-lowering in 
ischemic stroke, but the influence of statin pretreatment on outcomes remains contro-
versial [27]. Postoperative stroke occurred in 0.34% of a cohort of 36,634 consecutive 
postoperative patients, and this showed an almost flat distribution over the 30 days after 
surgery [28]. In hospitalized patients, there are various primary diseases including cancer, 
and treatment options such as surgery, chemotherapy, and radiation, which can increase 
the risk of stroke [29]. In this study, there was a high variability in D-dimer and fibrinogen 
levels in IHS patients; this may be a reflection of the variation in primary diseases and 
treatment options.
This study has several limitations. First, it was performed in the single stroke center of a 
university hospital. Patients’ backgrounds may vary depending on the hospital in which 
patients are treated. Second, surgery and other procedures can increase plasma D-dimer and 
fibrinogen levels; we could not determine why plasma D-dimer and fibrinogen levels were 
increased in the IHS group. Third, AF-related ischemic stroke may be underdiagnosed because 
resting and 24-h electrocardiogram are insufficient for detecting AF in most cases.
In conclusion, patients with IHS, especially those with active cancers, had poorer outcomes 
than patients with OHS. Importantly, elevated plasma levels of D-dimer and fibrinogen may 
be essential factors for detecting patients who have a high risk of a progression to IHS.
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